COSMOS Pharmaceutical Corporation (TYO:3349)
Japan
· Delayed Price · Currency is JPY 6,243.00
+33.00 (0.53%)
Apr 28, 2026, 3:30 PM JST
COSMOS Pharmaceutical Income Statement
Financials in millions JPY. Fiscal year is June - May.
Millions JPY. Fiscal year is Jun - May.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Feb '26 Feb 28, 2026 | May '25 May 31, 2025 | May '24 May 31, 2024 | May '23 May 31, 2023 | May '22 May 31, 2022 | May '21 May 31, 2021 | 2020 - 2016 |
| Revenue | 1,069,502 | 1,011,390 | 964,989 | 827,697 | 755,414 | 726,424 | Upgrade
|
| Revenue Growth (YoY) | 6.74% | 4.81% | 16.59% | 9.57% | 3.99% | 6.14% | Upgrade
|
| Cost of Revenue | 845,488 | 798,109 | 776,683 | 658,979 | 603,966 | 581,313 | Upgrade
|
| Gross Profit | 224,014 | 213,281 | 188,306 | 168,718 | 151,448 | 145,111 | Upgrade
|
| Selling, General & Admin | 183,670 | 152,430 | 138,536 | 122,807 | 107,756 | 99,163 | Upgrade
|
| Operating Expenses | 183,670 | 172,877 | 156,804 | 138,589 | 121,651 | 111,964 | Upgrade
|
| Operating Income | 40,344 | 40,404 | 31,502 | 30,129 | 29,797 | 33,147 | Upgrade
|
| Interest Expense | -433 | -254 | -99 | -51 | -52 | -60 | Upgrade
|
| Interest & Investment Income | 74 | 48 | 44 | 47 | 52 | 57 | Upgrade
|
| Other Non Operating Income (Expenses) | 2,775 | 2,961 | 2,852 | 2,960 | 3,063 | 2,690 | Upgrade
|
| EBT Excluding Unusual Items | 42,760 | 43,159 | 34,299 | 33,085 | 32,860 | 35,834 | Upgrade
|
| Gain (Loss) on Sale of Assets | 492 | - | 75 | - | 265 | 4,190 | Upgrade
|
| Asset Writedown | -320 | -508 | -1,010 | -113 | -70 | -31 | Upgrade
|
| Other Unusual Items | -73 | -280 | 355 | -200 | -8 | -1,398 | Upgrade
|
| Pretax Income | 42,807 | 42,371 | 33,719 | 32,772 | 33,047 | 38,595 | Upgrade
|
| Income Tax Expense | 11,424 | 11,393 | 9,265 | 8,975 | 9,892 | 11,439 | Upgrade
|
| Net Income | 31,383 | 30,978 | 24,454 | 23,797 | 23,155 | 27,156 | Upgrade
|
| Net Income to Common | 31,383 | 30,978 | 24,454 | 23,797 | 23,155 | 27,156 | Upgrade
|
| Net Income Growth | 6.60% | 26.68% | 2.76% | 2.77% | -14.73% | 26.69% | Upgrade
|
| Shares Outstanding (Basic) | 79 | 79 | 79 | 79 | 79 | 79 | Upgrade
|
| Shares Outstanding (Diluted) | 79 | 79 | 79 | 79 | 79 | 79 | Upgrade
|
| Shares Change (YoY) | - | 0.02% | 0.05% | - | - | - | Upgrade
|
| EPS (Basic) | 395.96 | 390.85 | 308.61 | 300.48 | 292.37 | 342.89 | Upgrade
|
| EPS (Diluted) | 395.96 | 390.85 | 308.61 | 300.48 | 292.37 | 342.89 | Upgrade
|
| EPS Growth | 6.60% | 26.65% | 2.71% | 2.77% | -14.73% | 26.69% | Upgrade
|
| Free Cash Flow | - | -859 | -635 | 7,798 | -11,303 | 1,811 | Upgrade
|
| Free Cash Flow Per Share | - | -10.84 | -8.01 | 98.46 | -142.72 | 22.87 | Upgrade
|
| Dividend Per Share | 75.000 | 70.000 | 60.000 | 50.000 | 40.000 | 35.000 | Upgrade
|
| Dividend Growth | 20.00% | 16.67% | 20.00% | 25.00% | 14.29% | 27.27% | Upgrade
|
| Gross Margin | 20.95% | 21.09% | 19.51% | 20.38% | 20.05% | 19.98% | Upgrade
|
| Operating Margin | 3.77% | 4.00% | 3.26% | 3.64% | 3.94% | 4.56% | Upgrade
|
| Profit Margin | 2.93% | 3.06% | 2.53% | 2.88% | 3.06% | 3.74% | Upgrade
|
| Free Cash Flow Margin | - | -0.08% | -0.07% | 0.94% | -1.50% | 0.25% | Upgrade
|
| EBITDA | 64,302 | 62,633 | 51,426 | 47,497 | 44,907 | 46,932 | Upgrade
|
| EBITDA Margin | 6.01% | 6.19% | 5.33% | 5.74% | 5.95% | 6.46% | Upgrade
|
| D&A For EBITDA | 23,958 | 22,229 | 19,924 | 17,368 | 15,110 | 13,785 | Upgrade
|
| EBIT | 40,344 | 40,404 | 31,502 | 30,129 | 29,797 | 33,147 | Upgrade
|
| EBIT Margin | 3.77% | 4.00% | 3.26% | 3.64% | 3.94% | 4.56% | Upgrade
|
| Effective Tax Rate | 26.69% | 26.89% | 27.48% | 27.39% | 29.93% | 29.64% | Upgrade
|
| Advertising Expenses | - | 1,561 | 1,812 | 1,648 | 1,632 | 2,784 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.